All In MedTech

Device Trial Radar · NCT07643467

Fluorescent Probe for Assessment of Renal Elimination

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Sep 1, 2026

Primary completion

May 31, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Aaron CookAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 11, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Accurate measures of kidney function is important for precision dosing of many medications. The current methods of determining kidney function largely hinge on the use of equations that use common laboratory values such as serum creatinine \& static variables like age \& weight. These are helpful for trending over time, but often are inaccurate during times of medical illness. Other more accurate methods of measuring kidney function include urine collection, although this is not commonly used because of various reasons that make the collection inconvenient or unreliable. The new transdermal glomerular filtration (tGFR) device permits accurate, real-time evaluation of kidney function. This novel method has not been rigorously compared with urine collection \& other methods of determining kidney function in hospitalized patients. The goal of the study is to compare tGFR with other accepted methods of determining kidney function.

Conditions

  • Augmented Renal Clearance
  • Critical Illness

Interventions

  • RelmapirazinDrug

    IV push of relmapirazin (Lumitrace) prior to use of the tGFR device

  • IohexolDrug

    Small IV push bolus of iohexol as a probe for renal function will be administered prior to use of the tGFR device.

  • Medibeacon tGFR monitorDevice

    The tGFR monitor will be applied to the patient after relmapirazin bolus for measurement of GFR.

  • Urine creatinine clearance collectionDiagnostic test

    8-hour urine creatinine clearance collection will be performed during the study period to compare to tGFR \& other renal function measures.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Transdermal Glomerular Filtration Rate (tGFR) Monitoring AccuracyTime frame: 8 Hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UKHealthCare/University of Kentucky

    Lexington, Kentucky · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.